DENND2D

Summary

DENND2D (DENN domain containing 2D, HGNC:26192) is a protein-coding gene on chromosome 1p13.3-p13.2, encoding DENN domain-containing protein 2D (Q9H6A0). Guanine nucleotide exchange factor (GEF) which may activate RAB9A and RAB9B.

Enables guanyl-nucleotide exchange factor activity. Located in cytosol and nucleoplasm.

Source: NCBI Gene 79961 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 82 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_024901

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26192
Approved symbol	DENND2D
Name	DENN domain containing 2D
Location	1p13.3-p13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22457, RP5-1180E21.2
Ensembl gene	ENSG00000162777
Ensembl biotype	protein_coding
OMIM	615111
Entrez	79961

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding_CDS_not_defined, 4 protein_coding

ENST00000357640, ENST00000369752, ENST00000463713, ENST00000468692, ENST00000473682, ENST00000473822, ENST00000477586, ENST00000488786, ENST00000900292, ENST00000900293

RefSeq mRNA: 2 — MANE Select: NM_024901 NM_001271833, NM_024901

CCDS: CCDS60219, CCDS831

Canonical transcript exons

ENST00000357640 — 12 exons

Exon	Start	End
ENSE00001068504	111192140	111192317
ENSE00001068505	111194578	111194726
ENSE00001068510	111195916	111196056
ENSE00001068513	111189212	111189253
ENSE00001433184	111200393	111200646
ENSE00003494377	111197176	111197253
ENSE00003501702	111199623	111199798
ENSE00003502040	111197920	111197989
ENSE00003550095	111188131	111188370
ENSE00003561912	111198630	111198742
ENSE00003684384	111188702	111188786
ENSE00003848799	111185969	111187681

Expression profiles

Bgee: expression breadth ubiquitous, 232 present calls, max score 98.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.4649 / max 499.4433, expressed in 1037 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13806	4.8088	332
13801	2.5043	307
13810	2.3742	827
13808	2.2617	181
13804	1.2257	238
13802	0.8377	219
13809	0.6589	293
201614	0.4042	214
13805	0.1439	60
13803	0.1139	72

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	98.59	gold quality
spleen	UBERON:0002106	96.62	gold quality
vermiform appendix	UBERON:0001154	96.29	gold quality
lymph node	UBERON:0000029	96.25	gold quality
blood	UBERON:0000178	96.25	gold quality
tonsil	UBERON:0002372	95.47	gold quality
lower esophagus mucosa	UBERON:0035834	95.31	gold quality
mucosa of transverse colon	UBERON:0004991	95.01	gold quality
rectum	UBERON:0001052	94.21	gold quality
esophagus mucosa	UBERON:0002469	94.08	gold quality
esophagus squamous epithelium	UBERON:0006920	93.34	gold quality
epithelium of nasopharynx	UBERON:0001951	93.25	gold quality
squamous epithelium	UBERON:0006914	92.58	gold quality
right uterine tube	UBERON:0001302	92.56	gold quality
tongue squamous epithelium	UBERON:0006919	92.40	gold quality
cervix squamous epithelium	UBERON:0006922	92.38	gold quality
epithelium of esophagus	UBERON:0001976	92.19	gold quality
minor salivary gland	UBERON:0001830	91.57	gold quality
caecum	UBERON:0001153	91.41	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.15	gold quality
mouth mucosa	UBERON:0003729	90.89	gold quality
amniotic fluid	UBERON:0000173	90.86	gold quality
right adrenal gland	UBERON:0001233	90.82	gold quality
right adrenal gland cortex	UBERON:0035827	90.80	gold quality
bone marrow cell	CL:0002092	90.66	gold quality
leukocyte	CL:0000738	90.60	gold quality
saliva-secreting gland	UBERON:0001044	90.18	gold quality
gingival epithelium	UBERON:0001949	90.16	gold quality
upper lobe of left lung	UBERON:0008952	90.15	gold quality
palpebral conjunctiva	UBERON:0001812	90.06	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-122	yes	40.02
E-ANND-3	yes	13.20
E-CURD-112	yes	5.42
E-MTAB-9067	yes	4.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

72 targeting DENND2D, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4255	99.72	67.70	1541

Literature-anchored findings (GeneRIF, showing 6)

• Mutations in DENND2D in melanoma by inhibition of nonsense-mediated mRNA decay. (PMID:18677770)
• Our data show that DENND2D might function as a tumor suppressor-like gene, preventing survival and expansion of cells with genetic damage through apoptosis mechanism. Absence of DENND2D might play a permissive role, as an early event, in tumorigenesis. (PMID:23182661)
• DENND2D is a candidate tumor suppressor gene that is inactivated by promoter hypermethylation in patients with Hepatocellular carcinoma and may serve as a novel biomarker of early recurrence of Hepatocellular carcinoma . (PMID:24189587)
• DENND2D is a candidate tumor suppressor gene that was inactivated by promoter hypermethylation in patients with esophageal squamous cell carcinoma and may serve as a novel biomarker of esophageal squamous cell carcinoma. (PMID:24317529)
• Higher frequency of promoter hypermethylation of DENND2D is associated with gastric cancer. (PMID:24695972)
• resulted in increased cell motility and invasive ability. Moreover, miR-1246 increased cell motility by directly targeting DENN/MADD Domain Containing 2D (DENND2D) (PMID:27929118)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dennd2db	ENSDARG00000030250
danio_rerio	dennd2da	ENSDARG00000058666
mus_musculus	Dennd2d	ENSMUSG00000027901
rattus_norvegicus	Dennd2d	ENSRNOG00000017680

Paralogs (3): DENND2A (ENSG00000146966), DENND2B (ENSG00000166444), DENND2C (ENSG00000175984)

Protein

Protein identifiers

DENN domain-containing protein 2D — Q9H6A0 (reviewed: Q9H6A0)

All UniProt accessions (1): Q9H6A0

UniProt curated annotations — full annotation on UniProt →

Function. Guanine nucleotide exchange factor (GEF) which may activate RAB9A and RAB9B. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form.

Subcellular location. Cytoplasm.

Tissue specificity. In bronchial mucosa, mainly expressed in ciliated and basal epithelial cells and weakly in alveolar cells (at protein level). Tends to be down-regulated in lung cancers, immortalized bronchial epithelial cell lines and precancerous lesions.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H6A0-1	1	yes
Q9H6A0-2	2

RefSeq proteins (2): NP_001258762, NP_079177* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001194	cDENN_dom	Domain
IPR005112	dDENN_dom	Domain
IPR005113	uDENN_dom	Domain
IPR037516	Tripartite_DENN	Domain
IPR043153	DENN_C	Homologous_superfamily
IPR051942	DENN_domain_containing_2	Family

Pfam: PF02141, PF03455, PF03456

UniProt features (7 total): domain 3, chain 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H6A0-F1	84.80	0.64

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8876198	RAB GEFs exchange GTP for GDP on RABs

MSigDB gene sets: 206 (showing top): BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, TGACCTY_ERR1_Q2, REACTOME_MEMBRANE_TRAFFICKING, WIELAND_UP_BY_HBV_INFECTION, TTGCWCAAY_CEBPB_02, MODULE_206, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, LEE_EARLY_T_LYMPHOCYTE_DN, GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_UP, MAF_Q6, AML1_01, DBP_Q6, MODULE_491, AP2GAMMA_01, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP

GO Biological Process (0):

GO Molecular Function (2): guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)

GO Cellular Component (3): nucleoplasm (GO:0005654), cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Rab regulation of trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
GTP binding	1
GDP binding	1
GTPase regulator activity	1
binding	1
nuclear lumen	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

608 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DENND2D	CHI3L2	Q15782	604
DENND2D	CIMAP3	Q8TCI5	517
DENND2D	CHIA	Q9BZP6	450
DENND2D	RAB9A	P51151	424
DENND2D	RHOBTB3	O94955	416
DENND2D	RAB9B	Q9NP90	397
DENND2D	NSUN2	Q08J23	384
DENND2D	ARHGAP18	Q8N392	375
DENND2D	TPP2	P29144	366
DENND2D	DOK3	Q7L591	326
DENND2D	HSF5	Q4G112	322
DENND2D	CEPT1	Q9Y6K0	322
DENND2D	BTG1	P31607	314
DENND2D	MPZL3	Q6UWV2	311
DENND2D	GPR155	Q7Z3F1	310

IntAct

10 interactions, top by confidence:

A	B	Type	Score
DENND2D	HSPA9	psi-mi:“MI:0915”(physical association)	0.620
FAM9B	DENND2D	psi-mi:“MI:0915”(physical association)	0.560
DENND2D	FAM9B	psi-mi:“MI:0915”(physical association)	0.560
DENND2D	HSPA8	psi-mi:“MI:0914”(association)	0.530
DENND2D	UBA52	psi-mi:“MI:0915”(physical association)	0.400
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
DENND2D	BAG3	psi-mi:“MI:0914”(association)	0.350

BioGRID (70): FAM9B (Two-hybrid), HSPA1B (Affinity Capture-MS), HSPA8 (Affinity Capture-MS), HSPA1L (Affinity Capture-MS), HSPA9 (Affinity Capture-MS), NOLC1 (Affinity Capture-MS), TCOF1 (Affinity Capture-MS), HSPA4 (Affinity Capture-MS), BRD2 (Affinity Capture-MS), TPP2 (Affinity Capture-MS), PNN (Affinity Capture-MS), ELL (Affinity Capture-MS), RNPS1 (Affinity Capture-MS), GRPEL1 (Affinity Capture-MS), COIL (Affinity Capture-MS)

ESM2 similar proteins: A2RT67, A2RUS2, A4D1U4, A7UA95, D4ACE5, F1ND48, O77682, O95870, P47823, Q059U7, Q08DJ7, Q09M05, Q0PGW2, Q13144, Q1JPD2, Q1LX49, Q3UHG7, Q3UMR0, Q4FZX0, Q4KLI9, Q4R4D7, Q4R8P0, Q4V7A9, Q5CZL1, Q5M7Q1, Q5R5N9, Q5R5S1, Q5R6S0, Q5REW9, Q5RL51, Q5XGM5, Q64350, Q6DDX8, Q6MG55, Q6NXD8, Q86V87, Q8CHW4, Q8JHZ8, Q8VDH1, Q91VV4

Diamond homologs: E9PXF8, G2WWH6, I1RQE2, O02626, O75064, O95248, P78524, Q3U1T9, Q3U1Y4, Q5VZ89, Q68D51, Q68F67, Q6NTN5, Q6P3S1, Q6ZPE2, Q7Z401, Q86WG5, Q8C4S8, Q8CFK6, Q8IV53, Q8K382, Q8TEH3, Q91VV4, Q924W7, Q9H6A0, Q9TXP3, Q9ULE3, Q9Y7Q7, X0JZ91, A6H8H2, O08873, Q6NXD8, Q6P9P8, Q6ZUT9, Q80U28, Q8WXG6, A2RSQ0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	61
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
545138	NC_000001.11:g.(?103175204)(111410059_?)del	Likely pathogenic

SpliceAI

2014 predictions. Top by Δscore:

Variant	Effect	Δscore
1:111188126:TGTA:T	donor_loss	1.0000
1:111188128:TAC:T	donor_loss	1.0000
1:111188129:AC:A	donor_loss	1.0000
1:111188130:C:CT	donor_loss	1.0000
1:111188160:T:TA	donor_gain	1.0000
1:111188695:GACTT:G	donor_loss	1.0000
1:111188696:ACTT:A	donor_loss	1.0000
1:111188697:CTTAC:C	donor_loss	1.0000
1:111188698:TTAC:T	donor_loss	1.0000
1:111188699:TAC:T	donor_loss	1.0000
1:111188700:A:AC	donor_gain	1.0000
1:111188700:AC:A	donor_loss	1.0000
1:111188700:ACT:A	donor_gain	1.0000
1:111188701:C:CA	donor_gain	1.0000
1:111188701:C:G	donor_loss	1.0000
1:111188701:CT:C	donor_gain	1.0000
1:111188701:CTC:C	donor_gain	1.0000
1:111195914:A:C	donor_loss	1.0000
1:111195915:C:CT	donor_loss	1.0000
1:111195919:AGTG:A	donor_gain	1.0000
1:111196052:AGGAT:A	acceptor_gain	1.0000
1:111196053:GGAT:G	acceptor_gain	1.0000
1:111196057:C:CC	acceptor_gain	1.0000
1:111198627:TA:T	donor_loss	1.0000
1:111198738:TCCCG:T	acceptor_gain	1.0000
1:111198739:CCCG:C	acceptor_gain	1.0000
1:111198739:CCCGC:C	acceptor_gain	1.0000
1:111198740:CCG:C	acceptor_gain	1.0000
1:111198740:CCGC:C	acceptor_gain	1.0000
1:111198741:CG:C	acceptor_gain	1.0000

AlphaMissense

3094 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:111192189:C:T	G308E	0.999
1:111195937:G:C	F208L	0.999
1:111195937:G:T	F208L	0.999
1:111195939:A:G	F208L	0.999
1:111195971:G:T	P197H	0.999
1:111197206:G:C	S158R	0.999
1:111197206:G:T	S158R	0.999
1:111197208:T:G	S158R	0.999
1:111197215:G:C	C155W	0.999
1:111197216:C:T	C155Y	0.999
1:111197217:A:G	C155R	0.999
1:111197932:G:C	C138W	0.999
1:111197939:C:T	G136E	0.999
1:111197969:A:G	L126P	0.999
1:111197980:G:C	F122L	0.999
1:111197980:G:T	F122L	0.999
1:111197982:A:G	F122L	0.999
1:111199629:A:C	F79L	0.999
1:111199629:A:T	F79L	0.999
1:111199631:A:G	F79L	0.999
1:111192190:C:G	G308R	0.998
1:111192190:C:T	G308R	0.998
1:111192265:A:G	W283R	0.998
1:111192265:A:T	W283R	0.998
1:111195940:G:C	S207R	0.998
1:111195940:G:T	S207R	0.998
1:111195942:T:G	S207R	0.998
1:111195971:G:C	P197R	0.998
1:111196033:T:A	R176S	0.998
1:111196033:T:G	R176S	0.998

dbSNP variants (sampled 300 via entrez): RS1000014248 (1:111201067 A>T), RS1000052281 (1:111205291 T>C), RS1000107183 (1:111192518 T>C), RS1000172709 (1:111205065 T>C), RS1000310503 (1:111192859 A>G), RS1000404108 (1:111200759 C>A,G), RS1000435119 (1:111200551 C>T), RS1000636596 (1:111196581 G>A), RS1000706402 (1:111195143 G>T), RS1000716073 (1:111205325 G>A), RS1000724987 (1:111188694 G>A), RS1000733615 (1:111202445 C>T), RS1001008594 (1:111196856 G>T), RS1001069495 (1:111189981 G>A,T), RS1001122123 (1:111190088 C>A,T)

Disease associations

OMIM: gene MIM:615111 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST001277_9	Liver enzyme levels (gamma-glutamyl transferase)	7.000000e-09
GCST004599_246	Mean platelet volume	5.000000e-17
GCST007430_17	Peak expiratory flow	3.000000e-07
GCST007431_110	Lung function (FEV1/FVC)	2.000000e-20
GCST007432_33	FEV1	6.000000e-12
GCST007692_75	Chronic obstructive pulmonary disease	3.000000e-10
GCST008481_1	Lung function (FEV1/FVC)	6.000000e-07
GCST90002385_617	High light scatter reticulocyte count	1.000000e-10
GCST90002386_370	High light scatter reticulocyte percentage of red cells	3.000000e-10
GCST90002389_67	Lymphocyte percentage of white cells	1.000000e-16
GCST90002395_315	Mean platelet volume	2.000000e-21
GCST90002395_316	Mean platelet volume	2.000000e-13
GCST90002399_3	Neutrophil percentage of white cells	2.000000e-18
GCST90002402_487	Platelet count	7.000000e-12
GCST90002405_77	Reticulocyte count	2.000000e-12
GCST90002406_148	Reticulocyte fraction of red cells	1.000000e-11
GCST90011899_159	Aspartate aminotransferase levels	2.000000e-08

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004532	serum gamma-glutamyl transferase measurement
EFO:0009718	peak expiratory flow
EFO:0004713	FEV/FVC ratio
EFO:0004314	forced expiratory volume
EFO:0007986	reticulocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes
EFO:0004309	platelet count
EFO:0004736	aspartate aminotransferase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
potassium chromate(VI)	affects cotreatment, decreases expression, increases expression	2
Air Pollutants	affects expression, increases abundance, increases expression	2
Air Pollutants, Occupational	affects expression, decreases expression	2
Benzo(a)pyrene	decreases methylation, increases expression	2
Nickel	decreases expression, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	affects expression, increases methylation	2
aristolochic acid I	decreases expression	1
daidzein	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
daidzin	affects cotreatment, increases expression	1
sodium arsenite	decreases expression	1
nickel sulfate	decreases expression	1
genistin	affects cotreatment, increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	affects expression	1
glycitein	affects cotreatment, increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
glycitin	increases expression, affects cotreatment	1
nutlin 3	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Zoledronic Acid	increases expression	1
Acetaminophen	decreases expression	1
Dactinomycin	increases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Methotrexate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms